Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Potential In China Monoclonal Antibody Drug Market

CRI Report - Under the new investment background in pharmaceutical industry, as to pharmaceutical enterprises, the innovation strategies and R&D trends of biological drugs, chemical drugs and Chinese patent drugs are definitely the key points for improving their competence. Monoclonal antibody drugs and vaccines have large development space. Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

According to research data, monoclonal antibody drug industry is at the top of biopharmaceutical pyramid with the global market scale exceeding USD 40 billion, positioning in drugs for tumour and severe immune system diseases. The average growth rate of the industry was over 50% in the past ten years. In addition, many heavyweight drugs with the sales revenue exceeding USD 5 billion appeared in the industry. Meanwhile, because of the high R&D barrier, only few pharmaceutical enterprises can enter the industry.Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

Among all biopharmaceutical drugs, monoclonal antibody drugs possess the largest market development potential with rapid growth rate and huge profit space. From 2013, China domestic monoclonal antibody drugs that have come into the market or is about to come into the market will lead a new round of rapid development in the industry. Presently, more products that are under R&D will promote the booming development of monoclonal antibody drug industry in 2016. Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

Although the overall technological level of China domestic monoclonal antibody drugs is comparatively laggard, the clinical examination and approval is obviously faster than that in the U.S. At present, CPGJ and Biotech Pharmaceutical Co., Ltd. have launched seven monoclonal antibody products into the market. China lacks mature platforms for developing monoclonal antibody drugs. Presently, the five products of Zhejiang Hisun Pharmaceutical Co., Ltd., CPGJ and so on are approved and put into production. Along with the above monoclonal antibody drugs becoming hot sell products in 2013-2016, China monoclonal antibody drug market will enter a period of rapid growth.Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

The reference listed drug of Anbainuo is the Enbrel (brand name) of Pfizer and the Enbrel is the first entirely-humanized soluble tumor necrosis factor antagonist for treating rheumatoid arthritis and ankylosing spondylitis. In 2005, CPGJ, a China domestic monoclonal antibody drug leading enterprise, launched "Etanercept" (generic drug of Enbrel) into the market. According to the fact that "Etanercept" creates the sales revenue of CNY 400 million to CNY 500 million every year for CPGJ, some insiders considered that the market development potential and sales volume of Anbainuo would bring about considerable contribution to Zhejiang Hisun Pharmaceutical Co., Ltd. Research Report on Global and China Monoclonal Antibody Industry, 2013-2017

In the segment fields of biopharmaceutical industry, vaccines become another hot land for assets. Mr. Li Xiangming, the secretary-general of China Pharmaceutical Research and Development Association and new drug review expert of China Food and Drug Administration, considers that vaccine industry shows an overall growth trend. Because of the R&D homogenization and the demand for large-scale channels, competitions among China domestic vaccine enterprises are intensified. At present, one vaccine variety is generally manufactured by five to ten enterprises, so the production capacity is obviously surplus. Meanwhile, each enterprise mainly focuses on developing HIB vaccines, multivalent meningitis vaccines, pneumonia vaccines and influenza vaccines with rather obvious "rush up in a crowd" phenomenon. Research Report on Global and China Monoclonal Antibody Industry, 2013-2017